Maravai Lifesciences Holdings, Inc. - MRVI STOCK NEWS

Maravai LifeSciences (NASDAQ: MRVI) will participate in several upcoming virtual investor conferences in June 2021. CFO Kevin Herde will speak at the William Blair Annual Growth Stock Conference on June 1, followed by another fireside chat at the Jefferies Healthcare Conference on June 2. CEO Carl Hull will present at the Goldman Sachs Healthcare Conference on June 10. Webcasts of these events will be available on the company's investor relations website, along with archived versions after each event.

Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI) reported a 190.7% increase in Q1 2021 revenue, reaching $148.2 million. Key drivers included a 306.5% surge in Nucleic Acid Production, totaling $123.9 million, fueled by strong demand for COVID-19 vaccine components. Biologics Safety Testing and Protein Detection also saw growth of 23.5% and 7.0% respectively. The company updated its 2021 revenue guidance to between $680 million and $720 million, reflecting anticipated growth of 139.4% to 153.5% over the year.

Maravai LifeSciences, Inc. (NASDAQ: MRVI) announced its participation in two upcoming virtual investor conferences in May 2021. CFO Kevin Herde will speak at the Bank of America Global Healthcare Conference on May 12 at 10:15 a.m. PT, while CEO Carl Hull will present at the UBS Global Healthcare Conference on May 25 at 2:00 p.m. PT. Live webcasts will be available on the Maravai investor relations website, with archived versions accessible shortly after each event. Maravai is known for its critical life science products supporting drug therapies, diagnostics, and research.

Maravai LifeSciences, Inc. (NASDAQ: MRVI) will announce its Q1 2021 financial results on May 10, 2021, after market close. A conference call is scheduled for the same day at 2:00 PM PT/5:00 PM ET. Participants can join by calling (833) 693-0536 or (661) 407-1576 using conference ID 4090862. An audio replay will be available for 72 hours after the call. Maravai is a leading provider of life science reagents and services, supporting drug therapy and vaccine development.

Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI) announced the closing of a public offering of 20.7 million shares of its Class A common stock by certain selling stockholders at $31.25 per share. This offering included the full exercise of underwriters' option for an additional 2.7 million shares. Notably, Maravai did not receive any proceeds from this sale. Major banks including Morgan Stanley and Jefferies served as joint book-running managers for the offering.

Maravai LifeSciences Holdings, Inc. (MRVI) announced an upsized public offering of 18,000,000 shares of Class A common stock at a price of $31.25 per share. This offering, increased by 3,000,000 shares from previous announcements, includes a 30-day option for underwriters to purchase an additional 2,700,000 shares. The offering is set to close on April 12, 2021. Notably, Maravai will not receive proceeds from this sale, which is managed by firms including Morgan Stanley, Jefferies, and Goldman Sachs.

Maravai LifeSciences Holdings (NASDAQ: MRVI) announced a public offering of 15,000,000 shares of its Class A common stock by selling stockholders, with an option for underwriters to purchase an additional 2,250,000 shares. The company will not receive any proceeds from this offering. Morgan Stanley, Jefferies, and Goldman Sachs are the joint managers for the offering. The registration statement is pending effectiveness, and the shares can't be sold until it becomes effective. Maravai provides essential life science products for drug therapies, diagnostics, and vaccine development.

Maravai LifeSciences Holdings, Inc. (MRVI) announced preliminary revenue estimates for Q1 2021, expecting approximately $148 million, which represents a 190% increase compared to Q1 2020 and a sequential rise of 50% from Q4 2020. The estimates exceed previous guidance of 30% to 35% growth. Income from Operations is projected to be between $80 million and $100 million. Revenues are primarily driven by strong performance in the Nucleic Acid Production segment, which accounts for $123.6 million, marking a 305% increase year-over-year.

Maravai LifeSciences (NASDAQ: MRVI) has enhanced its contract development and manufacturing capabilities with the launch of new plasmid DNA (pDNA) manufacturing services at TriLink BioTechnologies. This integrated offering aims to streamline the production of GMP-grade mRNA products, addressing the expected rise in global demand. CEO Carl Hull emphasized the importance of this development in reducing production timelines and alleviating sourcing delays. The state-of-the-art facility is equipped for GMP-grade plasmid production, supporting various therapeutic applications, including mRNA vaccines.